Newronika Receives CE Mark Approval for AlphaDBS, Advancing Adaptive Deep Brain Stimulation for Parkinson's Disease

Contributed by: PR Newswire

Images

PR Newswire associated0

Tags

Newronika-CE-Mark

More Like This

PR Newswire associated0

Newronika Receives CE Mark for αDBS®, Advancing Its Mission to Make Adaptive Therapy the Standard of Care

PR Newswire associated0

Newronika Receives Investigational Device Exemption (IDE) from FDA to Initiate U.S. Clinical Trial of Adaptive DBS System

PR Newswire associated0

Newronika Closes €13.6 Million Series B Financing to Accelerate Development of Adaptive DBS Platform

PR Newswire associated0

Newronika Appoints Keith Carlton as Executive Chairman to Reinforce Strategic Leadership

PR Newswire associated0

QuantalX Neuroscience Announces CE MDR Approval, Making Brain Health Assessment Available in the EU

PR Newswire associated0

Potential Add-on Treatment for Patients with Parkinson's Disease: Stimvia Completes Pilot Study and Announces Promising Initial Results

PR Newswire associated0

QuantalX Introduces a Breakthrough in the Diagnosis and Classification of Parkinson's Disease

Prothena Partners Present Data Supporting Next Generation Treatments for Parkinson’s and Alzheimer’s Disease at AD/PD™ 2026